🚨FDA Safety Alert🚨 - Orlistat The FDA (June 2026) has approved important labeling changes for orlistat, highlighting a rare but serious risk of acute kidney injury and kidney stones. 1 Key Update: Patients with a history of kidney disease or kidney stones should consult a healthcare professional before using orlistat. Rare cases of kidney injury have been reported, prompting updated safety warnings in the product labeling. Signs and symptoms may include: Back or groin pain Painful urination Blood in the urine Swelling of feet or legs ◆ Reduced urine output If these symptoms occur, patients should discontinue the medication and seek medical attention. Clinical Impact: Healthcare professionals should assess renal history before recommending orlistat for weight management. Patient counseling should now include awareness of potential kidney-related adverse effects and warning signs requiring prompt evaluation. https://t.me/PIC_uptodate77
FDA Safety Alert🚨 - Orlistat The FDA (June 2026) has approved… — Pharmacotherapy Information Center ( PIC ) — TG.ME
June 11, 2026 72
